Study funded by PharmaCielo compares impact of cultivation in Colombia, Washington and Colorado
TORONTO and RIONEGRO, Colombia, Sept. 6, 2017 /CNW/ - Global Footprint Network, an international nonprofit organization that is changing how the world manages its natural resources and responds to climate change, recently completed a study of the environmental impact of the regulated cannabis cultivation industry in three key locations, with funding support provided by PharmaCielo Ltd.
PharmaCielo, seeking to become the world's leading supplier of naturally grown and processed, standardized medicinal-grade cannabis oil extracts and related products, commissioned the study in order to ensure that its future planning and production are conducted in an environmentally responsible manner that can also be measured. "With the global cannabis industry still in its infancy, now is the essential time for the world to consider its resource demand and environmental impact. We needed this Ecological Footprint study, as there had not previously been any comprehensive assessment of the industry and its possible production techniques," said Dr. Patricio Stocker, President and CEO of PharmaCielo Ltd.
Global Footprint Network examined PharmaCielo operations in Colombia, as well as additional operators in Colorado and Washington State, USA, with the summarized results released in its most recent newsletter (http://www.footprintnetwork.org/2017/08/16/ecological-footprint-cannabis/).
The conclusion of the study was that while no cultivation is without environmental impact, the impact of the natural growing conditions afforded by PharmaCielo's cultivation methodology within Colombia's equatorial environment results in a dramatically smaller Ecological Footprint (10 global m2 / kg dried cannabis flower) than operators in the northern climates of Colorado (3700 global m2 / kg) or Washington (800 global m2 / kg) mostly due to the energy consumed for lighting and climate controlling the indoor production.
"In the development of a new industry, it is fundamental to examine the environmental consequences of any initiative before going forward," said Dr. Mathis Wackernagel, Ph.D., Founder and CEO of Global Footprint. "What we were able to learn through this study was the dramatic environmental difference and scale of the Ecological Footprint between cultivation in cannabis's natural environment vs. artificially structured ones."
About Global Footprint Network
Global Footprint Network is changing how the world manages its natural resources through:
For further information:
http://www.footprintnetwork.org
About PharmaCielo
PharmaCielo Ltd. is a global company privately held and headquartered in Canada, with a focus on processing and supplying all natural, medicinal-grade cannabis oil extracts and related products to large channel distributors. PharmaCielo's principal (and wholly-owned) subsidiary is PharmaCielo Colombia Holdings SAS, headquartered at its nursery and propagation centre located in Rionegro, Colombia.
The boards of directors and executive teams of both PharmaCielo and PharmaCielo Colombia Holdings are comprised of a diversely talented group of international business executives and specialists with relevant and varied expertise. PharmaCielo recognized the significant role that Colombia's ideal location will play in building a sustainable business in the medical cannabis industry, and the company, together with its directors and executives, has built a compelling business plan focused on supplying the international marketplace.
For further information:
www.PharmaCielo.com
This press release may contain forward-looking statements. Often, but not always, forward-looking statements can be identified by the use of words such as "plans", "expects" or "does not expect", "is expected", "estimates", "intends", "anticipates" or "does not anticipate", or "believes", or "recurring" or variations of such words and phrases or state that certain actions, events or results "may", "could", "would", "might" or "will" be taken, occur or be achieved. Forward-looking statements involve known and unknown risks, uncertainties and other factors, such as demand for the Company's products, currency exchange changes and risks, internal funding and the financial condition of the Company, product roll-out, competition, technological changes, and other commercial matters involving the Company, its products, and the markets in which the Company operates, as well as general economic conditions, which may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Actual results and developments are likely to differ, and may differ materially, from those expressed or implied by the forward-looking statements contained in this press release. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements.
Except as required by law, we undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise. However, any further disclosures made on related subjects in subsequent reports should be consulted.
SOURCE PharmaCielo
Media Inquiries: Global Footprint Network: Ronna Kelly - California, United States (PDT), Director of Communications and Marketing, Global Footprint Network, +1 (510) 839-8879 x 302, [email protected]; PharmaCielo: David Gordon, +1 647 259 3258, [email protected]; Juan Manuel Cuellar - Colombia, Tel: +57 310 3298776, [email protected]; Investor Inquiries: Tel: +1 647 560 4640, Toll Free 888 968 8279, [email protected]
Share this article